Gingko Biloba efficacy in treatment of drug-induced parkinsonism

Phase 2

Recruiting

• Conditions: drug-induced parkinsonism.; Other drug-induced secondary parkinsonism; G21.21

• Registration Number: IRCT20200708048060N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

All psychiatric patients with the symptoms of drug induced parkinsonism, who have been given neurological counseling and Parkinson's drug-induced event has been confirmed based on clinical judgments and other findings among them
Age over 18 years

Exclusion Criteria

Thrombocytopenia
Coagulopathy
Kidney failure
Liver failure
GI bleeding history
Consumption of warfarin, high dose NSAIDs or NSAIDS with SSRIs and CCBs.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improving the quality of life of patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: PDQ-39 questionnaire.;Improving the severity of drug induced parkinsonism symptoms in patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: Unified Parkinson's Disease Rating Scale ( UPDRS ) questionnaire Simpson-Angus Extrapyramidal Side Effects Scale (SAS ) questionnaire.;Improving the cognitive function in patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: MoCA (Montreal Cognitive Assessment) questionnaire.